SCHEMBL15933385

SCHEMBL15933385

Nc1ccccc1NC(=O)c1ccc(CNC(=O)c2cc3ccccc3s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 14/20 1.00
HDAC1 Q13547 10/20 0.78
HDAC3 O15379 5/20 0.61
NCOR2 Q9Y618 2/20 0.61
SENP5 Q96HI0 1/20 0.61
SENP2 Q9HC62 1/20 0.61
SENP1 Q9P0U3 1/20 0.61
HDAC4 P56524 2/20 0.57
HDAC7 Q8WUI4 2/20 0.57
HDAC10 Q969S8 2/20 0.57
HDAC11 Q96DB2 2/20 0.57
HDAC8 Q9BY41 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
HDAC9 Q9UKV0 2/20 0.57
HDAC5 Q9UQL6 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15933359 0.90 HDAC2 (1.00) HDAC2HDAC1HDAC3NCOR2SENP5
SCHEMBL15933360 0.88 HDAC2 (1.00) HDAC2HDAC1HDAC3NCOR2SENP5
SCHEMBL15652835 0.84 HDAC2 (0.72) HDAC2HDAC1HDAC3NCOR2SENP5
SCHEMBL3568732 0.84 HDAC2 (0.72) HDAC2HDAC1HDAC3SENP5SENP2
SCHEMBL3568348 0.84 HDAC2 (0.72) HDAC2HDAC1HDAC3SENP5SENP2
SCHEMBL12663172 0.83 HDAC2 (0.70) HDAC2HDAC1HDAC3HDAC4HDAC7
SCHEMBL6919078 0.83 HDAC1 (0.70) HDAC2HDAC1HDAC3NCOR2SENP5
SCHEMBL3579612 0.83 HDAC2 (0.70) HDAC2HDAC1
SCHEMBL3569534 0.83 HDAC2 (0.70) HDAC2HDAC1HDAC3NCOR2HDAC4
SCHEMBL3575412 0.82 HDAC2 (0.69) HDAC2HDAC1HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040727-B2 Histone deacetylase inhibitor of benzamides and use thereof SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-05-26 US disclosed
US-20140221431-A1 NOVEL HISTONE DEACETYLASE INHIBITOR OF BENZAMIDES AND USE THEREOF SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221431-A1 NOVEL HISTONE DEACETYLASE INHIBITOR OF BENZAMIDES AND USE THEREOF HDAC2, HDAC1, HDAC5 HDAC2 1/4885HDAC1 2/4885HDAC3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.